DOI: https://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20214927
Published: 2021-12-24

Expert opinion on current and emerging treatments in dermatophytosis

R. D. Kharkar, Mukesh Girdhar, Gautam Banerjee, T. Salim, Manas Sen, Susmit Haldar, Karthikeyan ., Ajey Kedia, Lipy Gupta, Rajesh Katariya

Abstract


Dermatophytosis continues to be a worldwide public health problem, predominantly in developing countries like India. Early diagnosis and appropriate management are imperative to enhance patient outcomes and improve quality of life of individuals with dermatophytosis. Multiple focused group discussions involving 76 dermatologists across 36 cities in India were conducted to provide a consensus clinical viewpoint of expert dermatologists to gain insights toward effective diagnosis and management of Indian subjects with dermatophytosis. These discussions mainly aimed at reviewing current literature on prevalence, etiology, diagnosis and management of dermatophytosis and highlighting variations in diagnostic and treatment approaches in routine clinical practice. The current article summarizes the experts’ clinical viewpoint on overall management of dermatophytosis. Diagnosis of dermatophytosis involves clinical observation, microscopic examination and dermoscopy. Molecular techniques have certain advantages over conventional microscopy and culture methods but are associated with issues of cost and technique complexity. Oral itraconazole 200 mg–400 mg daily and terbinafine 500 mg/day could be considered for recalcitrant tinea infections. Topical azoles like luliconazole, sertaconazole, and terbinafine could be beneficial. A combination of oral and topical antifungal drugs is effective in patients with steroid-modified and difficult-to-treat tinea infections. Also, patient counselling and use of adjunctive therapies like antihistamines, retinoids, and moisturizers are essential for managing tinea infections.  

 


Keywords


Dermatophytosis, Tinea infection, Antifungal

Full Text:

PDF

References


Rajagopalan M, Inamadar A, Mittal A, Miskeen AK, Srinivas CR, Sardana K, et al. Expert consensus on the management of dermatophytosis in India (ECTODERM India). BMC Dermatol. 2018;1:6.

Dogra S, Uprety S. The menace of chronic and recurrent dermatophytosis in India: Is the problem deeper than we perceive? Indian Dermatol Online J. 2016;2:73-6.

Ely JW, Rosenfeld S, Stone SM. Diagnosis and management of tinea infections. Am Fam Physician. 2014;10:702-10.

Sahoo AK, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review. Indian Dermatol Online J. 2016;2:77-86.

Nenoff P, Verma SB, Vasani R, Burmester A, Hipler UC, Wittig F, et al. The current Indian epidemic of superficial dermatophytosis due to Trichophyton mentagrophytes-A molecular study. Mycoses. 2019;4:336-56.

Verma S, Madhu R. The great Indian epidemic of superficial dermatophytosis: An appraisal. Indian J Dermatol. 2017;3:227-36.

Gandhi S, Patil S, Patil S, Badad A. Clinicoepidemiological study of dermatophyte infections in pediatric age group at a tertiary hospital in Karnataka. Indian J Paediatr Dermatol. 2019;20:52-6.

Kalita JM, Sharma A, Bhardwaj A, Nag VL. Dermatophytoses and spectrum of dermatophytes in patients attending a teaching hospital in Western Rajasthan, India. J Family Med Prim Care. 2019;4:1418-21.

Hainer BL. Dermatophyte infections. Am Fam Physician. 2003;1:101-8.

Sharma R, Adhikari L, Sharma RL. Recurrent dermatophytosis: A rising problem in Sikkim, a Himalayan state of India. Indian J Pathol Microbiol. 2017;4:541-5.

Balamuruganvelu S, Reddy SV, Babu G. Age and genderwise seasonal distribution of dermatophytosis in a tertiary care hospital, Puducherry, India. J Clin Diagn Res. 2019;13:WC06-10.

Tiwari S, Kumar D. A preliminary clinico-mycological study of dermatophytes infection. Int J Res Med Sci. 2018;12:3964-9.

Rengasamy M, Shenoy MM, Dogra S, Asokan N, Khurana A, Poojary S, et al. Indian association of dermatologists, venereologists and leprologists (IADVL) task force against recalcitrant tinea (ITART) consensus on the management of glabrous tinea (INTACT). Indian Dermatol Online J. 2020;4:502-19.

Begum J, Mir NA, Lingaraju MC, Buyamayum B, Dev K. Recent advances in the diagnosis of dermatophytosis. J Basic Microbiol. 2020;4:293-303.

Weinstein A, Berman B. Topical treatment of common superficial tinea infections. Am Fam Physician. 2002;10:2095-102.

Banerjee M, Ghosh AK, Basak S, Das KD, Gangopadhyay DN. Comparative evaluation of effectivity and safety of topical amorolfine and clotrimazole in the treatment of tinea corporis. Indian J Dermatol. 2011;6:657-62.

Sharma P, Bhalla M, Thami GP, Chander J. Evaluation of efficacy and safety of oral terbinafine and itraconazole combination therapy in the management of dermatophytosis. J Dermatolog Treat. 2020;7:749-53.

Mudge S, Lewis P, Burnett B. Relative bioavailability of a single oral dose of suba-itraconazole 65 mg capsule compared with conventional itraconazole 100 mg capsule administered under fasted and fed conditions in healthy adult volunteers. Open Forum Infect Dis. 2019;6:S761.

Gupta AK, Cooper EA, Ginter G. Efficacy and safety of itraconazole use in children. Dermatol Clin. 2003;3:521-35.

Bhat MR, Satheesh D, Jayaraman J. Effectiveness, safety, and tolerability of itraconazole oral solution in pediatric dermatophytosis. Indian J Paediatr Dermatol. 2020;21:259-63.

Prabhu SS, Sankineni P. Managing dermatophytoses in pregnancy, lactation, and children. Clin Dermatol Rev. 2017;1:S34-7.

Gupta AK, Konnikov N, Lynde CW. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. J Am Acad Dermatol. 2001;3:479-84.

Sardana K, Khurana A, Singh A, Gautam RK. A pilot analysis of morphometric assessment of itraconazole brands using dermoscopy and its relevance in the current scenario. Indian Dermatol Online J. 2018; 6:426-31.

Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother. 1999;8:1955-60.

Brown SJ. Efficacy of fluconazole for the treatment of onychomycosis. Ann Pharmacother. 2009;10:1684-91.

Sahni K, Singh S, Dogra S. Newer topical treatments in skin and nail dermatophyte infections. Indian Dermatol Online J. 2018;3:149-58.

Khurana A, Sardana K, Chowdhary A. Antifungal resistance in dermatophytes: Recent trends and therapeutic implications. Fungal Genet Biol. 2019;132:103255.

Patil A, Majumdar S. Echinocandins in antifungal pharmacotherapy. J Pharm Pharmacol. 2017;12:1635-60.

Pereda J, Noguera X, Boncompte E, Algueró M, Izquierdo I. Efficacy of flutrimazole 1% powder in the treatment of tinea pedis. Mycoses. 2003;46:126-31.

Albanese G, Di Cintio R, Giorgetti P, Galbiati G, Ciampini M. Recurrent tinea pedis: a double blind study on the prophylactic use of fenticonazole powder. Mycoses. 1992;35:157-9.

Jensen JM, Pfeiffer S, Akaki T, Schröder JM, Kleine M, Neumann C, et al. Barrier function, epidermal differentiation, and human beta-defensin 2 expression in tinea corporis. J Invest Dermatol. 2007;7:1720-7.

Arora R, Solanki. Comparative efficacy of mono therapy of oral itraconazole and oral itraconazole with isotretinoin in chronic and/or resistant superficial dermatophytosis. Paripex Indian J Res. 2018;7:9-11.

Becker C, Bershow A. Lasers and photodynamic therapy in the treatment of onychomycosis: a review of the literature. Dermatol Online J. 2013;9:19611.

Bhatta AK, Keyal U, Wang X, Gellén E. A review of the mechanism of action of lasers and photodynamic therapy for onychomycosis. Lasers Med Sci. 2017;2:469-74.

Piccolo D, Kostaki D, Del Duca E, Cannarozzo G, Sannino M, Nisticò S. Long-pulsed 1064-nm Nd:Yag laser for the treatment of onychomycosis. Photomed Laser Surg. 2017;4:213-6.

Lim EH, Kim HR, Park YO, Lee Y, Seo YJ, Kim CD, et al. Toenail onychomycosis treated with a fractional carbon-dioxide laser and topical antifungal cream. J Am Acad Dermatol. 2014;5:918-23.

Souza LW, Souza SV, Botelho AC. Randomized controlled trial comparing photodynamic therapy based on methylene blue dye and fluconazole for toenail onychomycosis. Dermatol Ther. 2014;1:43-7.

Tuknayat A, Bhalla M, Kaur A, Garg S. Familial dermatophytosis in India: A study of the possible contributing risk factors. J Clin Aesthet Dermatol. 2020;2:58-60.

Ghannoum MA, Mukherjee PK, Warshaw EM, Evans S, Korman NJ, Tavakkol A. Molecular analysis of dermatophytes suggests spread of infection among household members. Cutis. 2013;5:237-45.

Kaul S, Yadav S, Dogra S. Treatment of dermatophytosis in elderly, children, and pregnant women. Indian Dermatol Online J. 2017;5:310-8.